NuBiyota teams up with Takeda in new GI microbiome deal; Program discontinued
Takeda Pharmaceutical Co. Ltd. signed its second microbiome deal in less than a week, this time partnering with NuBiyota LLC to discover and develop new therapies for undisclosed gastroenterology conditions.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com